|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's range||118.85 - 121.05|
|52-week range||61.28 - 134.08|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||151.00|
With the business potentially at an important milestone, we thought we'd take a closer look at Sarepta Therapeutics...
Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
SOMERSET, N.J. & CAMBRIDGE, Mass., January 05, 2023--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dy